Can a Cancer Survivor Donate Plasma?

Whether a cancer survivor can donate plasma depends almost entirely on the type of cancer they had. People with a history of solid tumors like breast, colon, or skin cancer are accepted at the majority of collection centers once treatment is complete, while those who had blood cancers such as leukemia or lymphoma face a permanent ban at most facilities. The distinction comes down to where the cancer originated and how it might theoretically interact with donated blood products, though the scientific evidence behind many of these policies is thinner than you might expect.

Solid Tumors Versus Blood Cancers

A 2023 survey of blood collection centers found that donors with a history of carcinoma (cancers of organs and tissues) or sarcoma (cancers of bone and connective tissue) who had completed treatment were accepted at roughly three-quarters of responding centers with no additional waiting period at all.¹ That covers the vast majority of common cancers: breast, prostate, colon, lung, thyroid, skin, and many others. If you had one of these and your oncologist considers you done with treatment, most centers will let you donate.

Blood cancers tell a different story. The same survey found that about three-quarters of centers permanently deferred anyone with a history of leukemia or lymphoma, and an even higher proportion permanently deferred those with myelodysplastic or myeloproliferative syndromes.¹ “Permanent deferral” means what it sounds like: you are not eligible to donate, potentially ever, regardless of how long you have been in remission or how healthy you feel.

The logic behind the split is straightforward. Blood cancers originate in the bone marrow, lymph nodes, or blood-forming cells themselves. Even in remission, there is a theoretical concern that abnormal cells could be circulating in the donor’s blood at levels too low to detect but still present in the donated product. Solid tumors, by contrast, grow in a specific organ. While solid cancers can shed cells into the bloodstream, those cells are not “at home” in the blood the way leukemia cells are, and they have a much harder time surviving in a recipient’s body.

Cancers That Fall Into a Gray Zone

Not every cancer fits neatly into the accepted-or-deferred categories. Prostate cancer is a good example. Many men are diagnosed with low-grade prostate cancer and placed on active surveillance, meaning they are being monitored but not actively treated. The 2023 center survey noted that donors with cancer not in active treatment, such as prostate cancer under surveillance, were “subject to various deferrals,” meaning policies varied significantly from one facility to the next.¹ Some centers treated surveillance as equivalent to being cancer-free; others treated it as active cancer and deferred the donor.

Basal cell carcinoma, the most common skin cancer, is another frequent point of confusion. Most collection centers treat it as a minor exception to the cancer deferral discussion entirely. Because basal cell carcinoma almost never metastasizes beyond the skin and is typically cured with a simple excision, many blood banks allow donation once the surgical site has healed. The same is often true for squamous cell carcinoma of the skin when caught early, though policies can vary. If you had melanoma, the rules tend to be stricter, though again, many centers will accept you after treatment is complete.

Cervical carcinoma in situ (sometimes called stage 0 cervical cancer) is yet another edge case. Because it is confined to the surface layer of the cervix and is considered precancerous by many classification systems, some facilities do not count it as a cancer history at all for deferral purposes. If you are uncertain where your specific diagnosis falls, the only reliable way to find out is to call the donation center directly and describe your medical history before showing up.

Does the Evidence Actually Support These Rules?

Here is where things get interesting: the scientific basis for many cancer-related deferrals is remarkably weak. The same 2023 survey that cataloged center policies also conducted a literature review and found no evidence that cancer has ever been transmitted through a blood transfusion.¹ An earlier and more detailed review published in Transfusion Medicine Reviews reached the same conclusion, reporting that as of 2009, no single convincing case of cancer transmission via transfusion of peripheral blood had been identified in the medical literature.²

A large study published in The Lancet looked at the question from a different angle: what happens when someone unknowingly receives blood from a donor who later develops cancer? If transfusion could transmit cancer, you would expect recipients of those donations to have higher cancer rates. They did not. The study found no evidence that transfusions from precancerous donors increased cancer risk in recipients compared to transfusions from donors who never developed cancer.³

So the deferral policies, particularly the permanent bans on blood cancer survivors, are largely precautionary. They rest on a theoretical risk that has never been observed in practice. That does not mean the policies are wrong; precaution in blood banking has a long and generally vindicated history. But it does mean that if you are a leukemia survivor who feels frustrated about being permanently deferred, your frustration has some scientific backing. The rules are conservative by design, not because someone proved the danger is real.

Why Circulating Tumor Cells Are Not the Threat They Sound Like

One reason the theoretical concern has never materialized in practice is that circulating tumor cells, even when present in a donor’s blood, face enormous obstacles in a recipient’s body. A healthy immune system is remarkably good at destroying foreign cells. Tumor cells that have been removed from their original environment, diluted into a blood product, and then introduced into a person with a functioning immune system have almost no chance of establishing a new cancer. This is fundamentally different from organ transplantation, where recipients are given immunosuppressive drugs that deliberately weaken their ability to reject foreign tissue.

A 2021 paper in the Asian Pacific Journal of Cancer Prevention did propose that circulating tumor cells could theoretically pose a transmission risk through blood transfusion, and raised the topic as a hypothesis worth investigating given the volume of transfusions performed globally each year.⁴ But this was framed as a hypothesis for further study, not a documented risk. The actual observational data from large population studies, including the Lancet study described above, have consistently shown no increase in cancer among recipients of blood from donors who were harboring undiagnosed cancers at the time of donation.³ That is a powerful finding, because it means even when the system fails to screen out a donor with active cancer, the blood product does not appear to transmit the disease.

Plasma Donation Versus Whole Blood Donation

Most of the cancer deferral research and policy surveys deal with blood donation broadly, and in practice, the eligibility rules for plasma donation are nearly identical to those for whole blood. If you are eligible to donate whole blood as a cancer survivor, you are almost certainly eligible to donate plasma, and vice versa. The collection process is different (plasma donation uses a machine to separate the plasma and return red blood cells to you), but the medical screening criteria are drawn from the same guidelines.

There is one practical nuance worth knowing. The paid plasma industry, which collects source plasma for manufacturing into pharmaceutical products like immunoglobulin and clotting factors, sometimes operates under slightly different regulatory frameworks than volunteer blood banks that collect plasma for direct transfusion. The U.S. Food and Drug Administration regulates both, but commercial plasma centers may have their own corporate eligibility policies layered on top of FDA requirements. Some commercial centers are more permissive with cancer survivors; others are more restrictive. The eligibility screening questionnaire you complete at the center is the definitive word on whether they will accept you that day.

Plasma that is collected for pharmaceutical manufacturing also undergoes extensive processing, including pathogen inactivation steps, fractionation, and purification. These industrial processes break plasma down into its component proteins and remove or inactivate cells and cellular debris. Even the theoretical concern about circulating tumor cells becomes essentially moot when the plasma is going to be fractionated rather than transfused directly.

What About the Donor’s Own Safety?

The eligibility question usually focuses on recipient safety, but cancer survivors sometimes wonder whether donating blood or plasma could be harmful to them. The short answer is that donation is generally safe for people who have recovered from cancer, with the same minor risks that apply to anyone: lightheadedness, bruising at the needle site, and occasional fainting.

A study of over 3,400 therapeutic apheresis procedures (a process similar to plasma donation) found that adverse events occurred in about 5% of procedures, and the most common were vasovagal reactions like dizziness or fainting.⁵ Interestingly, these reactions were actually less common in hematology and oncology patients than in neurological patients undergoing the same procedure.⁵ While therapeutic apheresis is not identical to voluntary plasma donation, the physical process of drawing blood and returning cells through a machine is comparable enough that the safety profile is reassuring.

The bigger concern for some cancer survivors is whether their bodies have fully recovered from treatment. Chemotherapy can suppress bone marrow function and lower blood cell counts for months or even years after treatment ends. Radiation therapy can have similar lingering effects depending on the area treated. Most donation centers require that you have completed all treatment and that your blood counts are within normal ranges before they will accept you, which serves as a practical safeguard. If your hemoglobin, hematocrit, or other values are still recovering, you will be deferred on those grounds before the cancer history question even comes up.

What Happens When a Center Learns About Cancer After Donation

Sometimes a donor develops cancer shortly after giving blood or plasma, raising the question of whether the products already collected from them should be recalled or discarded. The 2023 center survey found that responses to post-donation cancer reports varied widely, with no consistent protocol across the industry.¹ Some centers would discard unused products; others would not, reasoning that the evidence for transfusion-transmitted cancer does not justify the waste.

This inconsistency reflects the broader tension in blood banking between precaution and evidence. Every unit of blood or plasma that gets discarded is a unit that cannot help a patient. Blood products are a limited resource, and overly aggressive deferral policies have real costs, not just to the donors who are turned away, but to the patients who need those products. The fact that cancer transmission through transfusion has never been documented weighs heavily in these decisions, even if no one is quite ready to abolish the deferrals entirely.

How Policies Differ Around the World

If you are reading this from outside the United States, your eligibility picture could look quite different. Blood banking regulations are set at the national level, and different countries have drawn different lines around cancer history. Some countries impose a mandatory waiting period after treatment completion, typically ranging from one to five years, even for solid tumors. Others follow the more permissive approach seen at most U.S. centers, allowing donation as soon as treatment is done. A few countries still maintain blanket permanent deferrals for any cancer history, regardless of type.

The trend over the past two decades has been toward liberalization. As the evidence base has grown showing no detectable risk of cancer transmission through transfusion, many blood services have relaxed their policies. The United Kingdom, for example, shortened its post-treatment deferral period for many cancers in recent years. Australia has taken a similar path. But change in blood banking is slow and deliberate, and some countries remain more cautious than the evidence alone would dictate, often because updating deferral criteria requires regulatory review processes that can take years.

Practical Steps If You Want to Donate

If you are a cancer survivor interested in donating plasma, the process is more straightforward than the policy landscape might suggest. Start by identifying the specific center where you plan to donate and contacting them before your visit. Give them your cancer type, the date of your last treatment, and your current health status. They will tell you whether you are eligible under their specific guidelines. Showing up without calling first risks wasting your time if their policy defers your cancer type.

Bring documentation if you have it. A letter from your oncologist confirming that treatment is complete and that you are in remission can smooth the screening process, especially at centers where staff may not be familiar with every cancer type’s deferral status. You are not required to bring this at most centers, but it can prevent a situation where a screener is uncertain and defaults to deferring you out of caution.

Be prepared for the possibility that different centers in the same city will give you different answers. As the survey data makes clear, there is no single national standard that every facility follows identically. One center’s permanent deferral is another center’s no-questions-asked acceptance, particularly for cancers in the gray zone like low-grade prostate cancer or early-stage melanoma. If you are turned away at one location, it is reasonable to ask elsewhere, though you should always be honest about your medical history on the screening questionnaire.

Emerging Research on Blood Product Safety

Researchers continue to develop new technologies that could make the theoretical concern about circulating tumor cells even less relevant than it already is. One line of work involves using coated magnetic nanoparticles to physically remove cancer cells from blood. A study published in ecancermedicalscience described a method using carboxymethyl dextran-coated nanoparticles paired with a magnetic separator that could deplete breast cancer cells from peripheral blood samples.⁶ This kind of technology is still in the research phase and is not used in routine blood banking, but it illustrates the direction the field is moving: toward tools that could make blood products safer at a cellular level, rather than relying solely on donor screening to keep unwanted cells out of the supply.

Pathogen reduction technologies, which are already used in some blood banks to inactivate viruses and bacteria in donated products, represent another avenue. These systems use ultraviolet light or chemical agents to damage the DNA of any cells or pathogens in the blood product, rendering them unable to replicate. While they were designed primarily to address infectious disease risk, they would in principle also neutralize any stray tumor cells. As these technologies become more widely adopted, the practical risk associated with any donor’s cancer history moves even closer to zero than it already is.

1
PubMed. The science…or not behind deferrals of blood donors with a history of cancer
2
Transfusion Medicine Reviews. Can Blood Tranfusion Transmit Cancer? A Literature Review
3
The Lancet. Risk of cancer transmission from blood and plasma donors to recipients
4
PubMed Central. Person-to-Person Cancer Transmission via Allogenic Blood Transfusion
5
PubMed. Frequency of immediate adverse effects associated with therapeutic apheresis
6
PubMed Central. High depletion of breast cancer cells from the peripheral blood with the method of non-specific separation